We are analyzing https://link.springer.com/article/10.1186/s12885-018-5263-z.

Title:
Statin use and breast cancer survival – a Swedish nationwide study | BMC Cancer
Description:
Background A sizeable body of evidence suggests that statins can cease breast cancer progression and prevent breast cancer recurrence. The latest studies have, however, not been supportive of such clinically beneficial effects. These discrepancies may be explained by insufficient power. This considerably sized study investigates the association between both pre- and post-diagnostic statin use and breast cancer outcome. Methods A Swedish nation-wide retrospective cohort study of 20,559 Swedish women diagnosed with breast cancer (July 1st, 2005 through 2008). Dispensed statin medication was identified through the Swedish Prescription Registry. Breast cancer related death information was obtained from the national cause-of-death registry until December 31st, 2012. Cox regression models yielded hazard ratios (HR) and 95% confidence intervals (CI) regarding associations between statin use and breast cancer-specific and overall mortality. Results During a median follow-up time of 61.6 months, a total of 4678 patients died, of which 2669 were considered breast cancer related deaths. Compared to non- or irregular use, regular pre-diagnostic statin use was associated with lower risk of breast cancer related deaths (HR = 0.77; 95% CI 0.63–0.95, P = 0.014). Similarly, post-diagnostic statin use compared to non-use was associated with lower risk of breast cancer related deaths (HR = 0.83; 95% CI 0.75–0.93, P = 0.001). Conclusion This study supports the notion that statin use is protective regarding breast cancer related mortality in agreement with previous Scandinavian studies, although less so with studies in other populations. These disparities should be further investigated to pave the way for future randomized clinical trials investigating the role of statins in breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, breast, statin, study, article, swedish, mortality, statins, survival, related, users, time, google, scholar, data, diagnosis, patients, women, table, dose, risk, cas, death, postdiagnostic, cohort, registry, prediagnostic, analyses, results, prescribed, analysis, nationwide, studies, december, deaths, age, information, effects, diagnosed, compared, regular, lower, years, cholesterol, treatment, access, borgquist, national, daily, lag,

Topics {✒️}

low-density-lipoprotein receptor resulting statin-induced anti-proliferative effects modeling exposure-lag-response associations inhibiting hmg-coa reductase early-stage breast cancer breast cancer-specific mortality reduced cancer-related mortality breast cancer recurrence/mortality population-based cohort study potential confounding factors post-diagnostic statin user regular-user criteria stated life-style factors regular pre-diagnostic statin regular pre-diagnostic users article download pdf post-diagnostic statin users mortality pre-diagnostic statin breast cancer related pre-diagnostic statin users pre-diagnostic statin users swedish research council reasonable lag-time estimate disease-specific survival pre-diagnostic statin usage breast cancer survival breast cancer prognosis evaluating pre-diagnostic statin randomized clinical trials privacy choices/manage cookies mortality significantly compared year lag-time based breast cancer-specific previously published studies swedish cancer registry breast cancer progression breast cancer recurrence breast cancer cases breast cancer stage breast cancer recurrences breast cancer outcomes breast cancer pathogenesis breast cancer pathophysiology female breast cancer male breast cancer primary breast cancer positive breast cancer swedish nationwide study prospective cohort study creative commons license

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Statin use and breast cancer survival – a Swedish nationwide study
         description:A sizeable body of evidence suggests that statins can cease breast cancer progression and prevent breast cancer recurrence. The latest studies have, however, not been supportive of such clinically beneficial effects. These discrepancies may be explained by insufficient power. This considerably sized study investigates the association between both pre- and post-diagnostic statin use and breast cancer outcome. A Swedish nation-wide retrospective cohort study of 20,559 Swedish women diagnosed with breast cancer (July 1st, 2005 through 2008). Dispensed statin medication was identified through the Swedish Prescription Registry. Breast cancer related death information was obtained from the national cause-of-death registry until December 31st, 2012. Cox regression models yielded hazard ratios (HR) and 95% confidence intervals (CI) regarding associations between statin use and breast cancer-specific and overall mortality. During a median follow-up time of 61.6 months, a total of 4678 patients died, of which 2669 were considered breast cancer related deaths. Compared to non- or irregular use, regular pre-diagnostic statin use was associated with lower risk of breast cancer related deaths (HR = 0.77; 95% CI 0.63–0.95, P = 0.014). Similarly, post-diagnostic statin use compared to non-use was associated with lower risk of breast cancer related deaths (HR = 0.83; 95% CI 0.75–0.93, P = 0.001). This study supports the notion that statin use is protective regarding breast cancer related mortality in agreement with previous Scandinavian studies, although less so with studies in other populations. These disparities should be further investigated to pave the way for future randomized clinical trials investigating the role of statins in breast cancer.
         datePublished:2019-01-11T00:00:00Z
         dateModified:2019-01-11T00:00:00Z
         pageStart:1
         pageEnd:9
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12885-018-5263-z
         keywords:
            Statin
            Breast cancer
            Survival
            Prognosis
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-018-5263-z/MediaObjects/12885_2018_5263_Fig1_HTML.png
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:19
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Signe Borgquist
               url:http://orcid.org/0000-0001-7938-8893
               affiliation:
                     name:Division of Oncology and Pathology, Department of Clinical Sciences
                     address:
                        name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
                        type:PostalAddress
                     type:Organization
                     name:Aarhus University Hospital
                     address:
                        name:Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Per Broberg
               affiliation:
                     name:Lund University
                     address:
                        name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jasaman Tojjar
               affiliation:
                     name:Lund University
                     address:
                        name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Håkan Olsson
               affiliation:
                     name:Division of Oncology and Pathology, Department of Clinical Sciences
                     address:
                        name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
                        type:PostalAddress
                     type:Organization
                     name:Lund University
                     address:
                        name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Statin use and breast cancer survival – a Swedish nationwide study
      description:A sizeable body of evidence suggests that statins can cease breast cancer progression and prevent breast cancer recurrence. The latest studies have, however, not been supportive of such clinically beneficial effects. These discrepancies may be explained by insufficient power. This considerably sized study investigates the association between both pre- and post-diagnostic statin use and breast cancer outcome. A Swedish nation-wide retrospective cohort study of 20,559 Swedish women diagnosed with breast cancer (July 1st, 2005 through 2008). Dispensed statin medication was identified through the Swedish Prescription Registry. Breast cancer related death information was obtained from the national cause-of-death registry until December 31st, 2012. Cox regression models yielded hazard ratios (HR) and 95% confidence intervals (CI) regarding associations between statin use and breast cancer-specific and overall mortality. During a median follow-up time of 61.6 months, a total of 4678 patients died, of which 2669 were considered breast cancer related deaths. Compared to non- or irregular use, regular pre-diagnostic statin use was associated with lower risk of breast cancer related deaths (HR = 0.77; 95% CI 0.63–0.95, P = 0.014). Similarly, post-diagnostic statin use compared to non-use was associated with lower risk of breast cancer related deaths (HR = 0.83; 95% CI 0.75–0.93, P = 0.001). This study supports the notion that statin use is protective regarding breast cancer related mortality in agreement with previous Scandinavian studies, although less so with studies in other populations. These disparities should be further investigated to pave the way for future randomized clinical trials investigating the role of statins in breast cancer.
      datePublished:2019-01-11T00:00:00Z
      dateModified:2019-01-11T00:00:00Z
      pageStart:1
      pageEnd:9
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12885-018-5263-z
      keywords:
         Statin
         Breast cancer
         Survival
         Prognosis
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-018-5263-z/MediaObjects/12885_2018_5263_Fig1_HTML.png
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:19
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Signe Borgquist
            url:http://orcid.org/0000-0001-7938-8893
            affiliation:
                  name:Division of Oncology and Pathology, Department of Clinical Sciences
                  address:
                     name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
                     type:PostalAddress
                  type:Organization
                  name:Aarhus University Hospital
                  address:
                     name:Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Per Broberg
            affiliation:
                  name:Lund University
                  address:
                     name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jasaman Tojjar
            affiliation:
                  name:Lund University
                  address:
                     name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Håkan Olsson
            affiliation:
                  name:Division of Oncology and Pathology, Department of Clinical Sciences
                  address:
                     name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
                     type:PostalAddress
                  type:Organization
                  name:Lund University
                  address:
                     name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:19
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Division of Oncology and Pathology, Department of Clinical Sciences
      address:
         name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
         type:PostalAddress
      name:Aarhus University Hospital
      address:
         name:Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
         type:PostalAddress
      name:Lund University
      address:
         name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
         type:PostalAddress
      name:Lund University
      address:
         name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
         type:PostalAddress
      name:Division of Oncology and Pathology, Department of Clinical Sciences
      address:
         name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
         type:PostalAddress
      name:Lund University
      address:
         name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Signe Borgquist
      url:http://orcid.org/0000-0001-7938-8893
      affiliation:
            name:Division of Oncology and Pathology, Department of Clinical Sciences
            address:
               name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
               type:PostalAddress
            type:Organization
            name:Aarhus University Hospital
            address:
               name:Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Per Broberg
      affiliation:
            name:Lund University
            address:
               name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Jasaman Tojjar
      affiliation:
            name:Lund University
            address:
               name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Håkan Olsson
      affiliation:
            name:Division of Oncology and Pathology, Department of Clinical Sciences
            address:
               name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
               type:PostalAddress
            type:Organization
            name:Lund University
            address:
               name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
      name:Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
      name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
      name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden
      name:Division of Oncology and Pathology, Department of Clinical Sciences, Lund, Sweden
      name:Division of Cancer Epidemiology, Department of Clinical Sciences, Lund University, Lund, Sweden

External Links {🔗}(84)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.83s.

LINK . SPRINGER . COM {}